GIRL-H: Girls and women improving resilience through livelihoods and health - Prosper Global

Following the devastation of the past three years, productive capacity in Gaza has been severely damaged, markets disrupted and the cost of basic goods has risen sharply. Their experiences reflect different parts of the same challenge: sustaining livelihoods that still exist, helping businesses restart and creating new opportunities where livelihoods have disappeared. Running a business today means navigating uncertainty at every turn. Yet amid these challenges, women continue to find ways to work, adapting their businesses, learning new skills and somehow – supporting their families. Nidaa: A livelihood built from childhoodNidaa, 35, has her own business raising and selling chickens, ducks and rabbits in the southern city of Khan Younis. “I was passionate about this business since I was a child,” she said. “My mother worked with animals, and she taught me everything she knew. During the war, I faced many challenges with continuing my business. However, I insisted on continuing.”When her home was destroyed during the war and she was displaced, she managed to save some of her animals and move them to Khan Younis.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.